A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.
Rustin, G Reed, N Jayson, Gordon C Ledermann, J A Adams, M Perren, T Poole, C Lind, M Persic, M Essapen, S
Rustin, G
Reed, N
Jayson, Gordon C
Ledermann, J A
Adams, M
Perren, T
Poole, C
Lind, M
Persic, M
Essapen, S
Citations
Altmetric:
Abstract
Sagopilone, the first fully synthetic epothilone, has shown promising preclinical activity in tumour models. This open-label randomised phase II study investigated two infusion schedules of sagopilone in women with ovarian cancer.
Description
Date
2011-11
Publisher
Collections
Keywords
Type
Article
Citation
A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. 2011, 22 (11):2411-6 Ann Oncol